The Latest Breaking News from EXAS

In a world where generative AI is running amok, we can use empirical axioms to tilt the odds in our favor.

This top-rated healthcare stock is poised for substantial growth after securing FDA approval for its innovative non-invasive cancer diagnostic.

Exact Sciences Corp's (NASDAQ:EXAS) Q1 revenues increased 21% Y/Y to $486.6 million, beating the average Wall Street estimate of $461.71 million. Excluding COVID-19 testing revenues, which dropped 15% to $27.4 million, Exact's Q1 revenue increased 24%.  Screening revenues rose 28% to $306.5 million in Q1, while Precision Oncology revenues were up 18%…

Within the last quarter, Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings:

Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 20 years by 2.83% on an annualized basis producing an average annual return of 10.04%. Currently, Exact Sciences has a market capitalization of $11.93 billion.

The COVID-19 pandemic has accelerated digital adoption in healthcare. And because this trend is attracting massive investments into digital health care, Wall Street analysts expect popular health tech stocks Exact Sciences Corp (EXAS), GoodRx Holdings (GDRX), 23andMe (ME) to rally in price soon. Read on.

Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 5 years by 12.08% on an annualized basis.

Renowned institutional investor Cathie Wood of Ark Investments fame is known for her market-beating investment strategies. Ark’s portfolio companies are attractive investments due to their long-term high growth potential and ability to withstand the current industry headwinds. Thus, Wall Street analysts expect fundamentally solid Cathie Wood stocks Coinbase (COIN), Zoom…

Over the past 3 months, 4 analysts have published their opinion on Exact Sciences (NASDAQ:EXAS) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.